https://www.cohenveteransbioscience.org/wp-content/themes/cvb-theme/assets/img/icon-news-card.png
Cross-Platform Evaluation of Commercial Metabolomics Platforms to Support Precision Therapeutics Research
As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or "bakeoff") of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.
Share this article:
More from CVB
https://www.cohenveteransbioscience.org/wp-content/uploads/2024/01/cv.webp
Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder
https://www.cohenveteransbioscience.org/wp-content/uploads/2022/11/bigstock-Dna-With-Unique-Connection-155670029.jpg
New meta-analysis builds upon PTSD genetics research, providing a foundation for the development of precision therapies
https://www.cohenveteransbioscience.org/wp-content/uploads/2022/06/CVB-Circuit-Newsletter-Header.png
The Circuit – April 2024
About Cohen Veterans Bioscience (CVB)
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
For Media Inquiries
Please feel free to email us at media@cohenbio.org
